New Test Diagnoses Cancer Faster, Offers Patients Better Treatment
BOSTON (CBS) – Dr. Mallika Marshall moderated a panel at the 2016 World Medical Innovation Forum Wednesday and learned of a new test that is being used to diagnose and help direct care for patients with certain cancers. “You gotta be kidding me,” was David Gill’s first thought when his doctors told him he had cancer last year. “I had no symptoms. No nothing,” Gill said. The 59-year old Army veteran from Greenland, New Hampshire was diagnosed with myelodysplastic syndrome MDS, a blood cancer which quickly started to transform into acute leukemia. David Gill (WBZ-TV) “Acute leukemia ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 27, 2016 Category: Consumer Health News Authors: deanreddington Tags: Health Local News Seen On WBZ-TV Syndicated Local Watch Listen Dr. Mallika Marshall Rapid Heme Test Source Type: news

What Are Common Causes of Congenital Aplastic Anemia?
Discussion Aplastic anemia are disorders where there is inadequate production of erythrocytes, granulocytes and platelets caused by decreased bone marrow production leading to a peripheral blood pancytopenia. Most often it is acquired because of exposures to infections (especially viruses such as Epstein-Barr virus, rubella, herpes, etc.), drugs (e.g. chloramphenicol, chemotherapeutic agents, etc.), toxins or radiation. Learning Point The most common congenital bone marrow failure syndromes causing pancytopenia are (in this order) Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond anemia. Most have a variety of...
Source: PediatricEducation.org - April 17, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

For college athlete-turned transplant patient, life’s still a ball
The first time a stem cell transplant recipient leaves his or her quarantined hospital room marks a significant milestone. In the case of Dana Mendes, this move toward independence included an additional step: chasing a ball through the hallways with a stick. For Mendes, 18, it was a return to what she loves. She had been just two days away from her first preseason field hockey practice at Assumption College in August 2015 when a mysterious bout of fatigue was diagnosed as myelodysplastic syndrome (MDS). This precancerous condition, in which immature blood cells in the bone marrow do not mature to become healthy blood cell...
Source: Thrive, Children's Hospital Boston - April 5, 2016 Category: Pediatrics Authors: Saul Wisnia Tags: Diseases & Conditions Our Patients’ Stories Dana-Farber/Boston Children's Cancer and Blood Disorders Center myelodysplastic syndrome stem cell transplant Source Type: news

Seattle Genetics begins trial of vadastuximab talirine combination therapy in MDS patients
US-based Seattle Genetics has started a Phase I/II clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza), a hypomethylating agent (HMA), in patients with previously untreated myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - February 23, 2016 Category: Pharmaceuticals Source Type: news

Azacitidine-Induced Cryptogenic Organizing PneumoniaAzacitidine-Induced Cryptogenic Organizing Pneumonia
This case report highlights an important, potentially treatable and rare side effect of azacitidine, a hypomethylating agent used in the treatment of myelodysplastic syndrome. Journal of Medical Case Reports (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 18, 2016 Category: Intensive Care Tags: Hematology-Oncology Journal Article Source Type: news

Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
First Phase 3 Data From Placebo-Controlled Study With an Erythropoiesis-Stimulating Agent (ESA) in Anemic Patients With MDS Study Met Primary Endpoint and Key Secondary Endpoint of Erythroid Response THOUSAND OAKS, Calif., Feb. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk MDS at the end of the blinded 25-week study period. Aranesp also significantly improved ...
Source: Amgen News Release - February 15, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Summary Information for: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Labeling, Approval Order, and Summary of Safety and Effectiveness for PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) (H140005). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 14, 2016 Category: Medical Equipment Source Type: news

McMaster researchers reveal predictive staircase to leukemia
(McMaster University) In the paper published today by the scientific journal Cancer Cell, the researchers detail how they have been able to fingerprint myelodysplastic syndromes, a state for blood cells that turns into acute myeloid leukemia cancer in approximately 30 percent of patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 11, 2016 Category: Cancer & Oncology Source Type: news

Study shows age doesn't affect survival outcomes in patients with MDS who receive a HCT
(Padilla Speer Beardsley) Prospective study, presented at the 57th Annual Meeting of the American Society of Hematology, shows age doesn't affect survival outcomes in patients with myelodysplastic syndrome (MDS) who receive a hematopoietic cell transplant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 6, 2015 Category: Global & Universal Source Type: news

Temple & Fox Chase Cancer Center testing drug for cancer & bone marrow disorders
(Temple University Health System) Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine (SGI-110) in Myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). MDS are a group of bone marrow disorders in which the bone marrow doesn't produce enough healthy blood cells. AML is a cancer of the blood and bone marrow. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 18, 2015 Category: Cancer & Oncology Source Type: news

Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research and Development Expert, To Board of Directors
BEVERLY HILLS, Calif., Aug. 11, 2015 -- (Healthcare Sales & Marketing Network) -- Rich Pharmaceuticals, Inc. (RCHAE) ("Rich Pharmaceuticals" or the "Company") announced today that Dr. Richard A. Salvador will be joining the corporate b... Biopharmaceuticals, Oncology, PersonnelRich Pharmaceuticals, Acute Myelocytic Leukemia, Myelodysplastic Syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 11, 2015 Category: Pharmaceuticals Source Type: news

Case study reveals therapy to reduce sarcoidosis symptoms in 5q-myelodysplastic syndrome
(American College of Chest Physicians) A case study published in the August issue of the journal CHEST found lenalidomide treatments may have an immediate effect in the treatment of sarcoidosis-related symptoms. Sarcoidosis, a disease that involves abnormal collections of inflammatory cells that can form nodules in various organs, can affect individuals from all racial and age groups. To date, no optimal therapies have been effective in managing this condition. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2015 Category: Global & Universal Source Type: news

Trial could impact older myelodysplastic syndrome population's access to bone marrow transplants
An America-wide clinical trial analyzes outcomes after two common treatments: bone marrow transplant and chemotherapy. The results could lead to wider access to transplants, researchers say. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 23, 2015 Category: Science Source Type: news

BBC bosses launch Save Our Sue bid for Sue Lloyd-Roberts who has cancer
Sue Lloyd-Roberts, 62, says it is ‘a race against time’ to have a cell transplant after she was diagnosed with blood disorder myelodysplastic syndrome that had developed into leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - June 18, 2015 Category: Consumer Health News Source Type: news

Study may suggest new strategies for myelodysplastic syndromes treatment
(University of Texas M. D. Anderson Cancer Center) A study revealing fresh insight about chromosome 'tails' called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 11, 2015 Category: Cancer & Oncology Source Type: news

Study May Suggest New Strategies for Myelodysplastic Syndromes Treatment
A study revealing fresh insight about chromosome "tails" called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes (MDS). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - May 11, 2015 Category: Cancer & Oncology Source Type: news

What is myelodysplastic syndrome (MDS)?
When a 6-year-old boy who loves Facebook missed Halloween because of a rare blood disorder, inpatient nurses at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center stepped in. They organized a belated Halloween celebration, and Boston Children’s Hospital posted a photo on its Facebook page, along with a request “to show him support and cheer him on.” Now it was Facebook users’ turn to step in, and step in they did. By the next morning, the post had more than 10,000 likes. Local media and Dana-Farber Cancer Institute posted the story on their Facebook pages, leading to thousands mor...
Source: Thrive, Children's Hospital Boston - April 1, 2015 Category: Pediatrics Authors: Irene Sege Tags: Cancer Source Type: news

Researchers discover genetic origins of myelodysplastic syndrome using stem cells
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Induced pluripotent stem cells (iPSCs) -- adult cells reprogrammed back to an embryonic stem cell-like state -- may better model the genetic contributions patient's particular disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2015 Category: Global & Universal Source Type: news

Myelodysplastic Syndromes / Myeloproliferative Disorders
What are myelodysplastic syndromes?Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterized by ineffective hemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukemia in a third of patients. Who is affected?15% of cases occur after chemotherapy or radiotherapy for a previous cancer. The syndromes are most common in elderly people. What is the cause?The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages. What are the symptoms?Clinical manifestations result from cytopenias (anemia, infection, and b...
Source: Clinical Cases and Images - March 3, 2015 Category: Journals (General) Tags: Hematology Mayo Clinic Oncology Video Source Type: news

Healthy older adults carry leukaemia mutations
Conclusion This study estimated that 0.8% of individuals under 60, and 19.5% of those aged 90 years and over, had leukaemia-linked mutations. These mutations caused no immediate harm and the people didn’t have leukaemia. The mutations were lurking in the background, but could have the potential to contribute to leukaemia in the future. The research primarily focused on 15 genetic hotspots of leukaemia-linked mutations. However, in their discussion, they predicted that more than 70% of people aged 90 or older would have some form of leukaemia-associated mutation. This formed the basis of their comment that these mutat...
Source: NHS News Feed - February 27, 2015 Category: Consumer Health News Tags: Cancer Genetics/stem cells Older people Source Type: news

Opsona begins Phase I/II trial of OPN-305 to treat second-line lower MDS
Irish drug development firm Opsona Therapeutics has started a Phase I/II clinical trial of its lead drug candidate, OPN-305, in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - January 27, 2015 Category: Pharmaceuticals Source Type: news

FASEB Science Research Conference: Hematologic Malignancies
(Federation of American Societies for Experimental Biology) This FASEB Science Research Conference has a long pedigree as one of the premier meetings for fundamental and translational research in the hematologic malignancies including acute and chronic leukemia, the myeloproliferative neoplasms, myelodysplastic syndromes, myeloma and lymphoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2015 Category: Global & Universal Source Type: news

MD Anderson and Amgen announce agreement to develop BiTE® therapies for myelodysplastic syndrome
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a 'bridge' between T cells and cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 12, 2015 Category: Global & Universal Source Type: news

MD Anderson and Amgen announce agreement to develop BiTE® therapies for myelodysplastic syndrome
The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 12, 2015 Category: Cancer & Oncology Source Type: news

Novel Agent Reduces Need for Transfusion in MDSNovel Agent Reduces Need for Transfusion in MDS
The first-in-class investigational agent sotatercept reduced the transfusion burden in ESA-refractory, anemic, lower-risk patients with myelodysplastic syndromes (MDS). Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Combination therapy shown as effective for higher-risk MDS/AML patients
(University of Texas M. D. Anderson Cancer Center) A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2014 Category: Cancer & Oncology Source Type: news

Combination Therapy Shown As Effective For Higher-Risk MDS/AML Patients
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2014 Category: Cancer & Oncology Source Type: news

Studies Find Detectable Pre-cancerous State in the Blood
Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, which was made independently by two research teams affiliated with the Broad and partner institutions, opens new avenues for research aimed at early detection and prevention of blood cancer. Findings from both teams appear this week in the New England Journal of ...
Source: Disabled World - November 27, 2014 Category: Disability Tags: Treatments Source Type: news

Studies Find Detectable Pre-cancerous State in the Blood
Researchers uncover easily detectable pre-malignant state in blood that increases likelihood a person will develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome (Source: Disabled World)
Source: Disabled World - November 27, 2014 Category: Disability Tags: Treatment of Cancer Source Type: news

Two studies identify a detectable, pre-cancerous state in the blood
(Broad Institute of MIT and Harvard) Researchers from the Broad Institute, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, 'pre-malignant' state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, which was made independently by two research teams affiliated with the Broad and partner institutions, opens new avenues for research aimed at early detection and prevention of blood cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 26, 2014 Category: Biology Source Type: news

Moffitt Cancer Center announces development of experimental treatment for myelodysplastic syndromes
(H. Lee Moffitt Cancer Center & Research Institute) In a major step to treat patients living with Myelodysplastic Syndromes, a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2014 Category: Cancer & Oncology Source Type: news

Geron lands potential $900M blood cancer drug deal with J&J
Geron Corp. will hand over its experimental blood cancer drug imetelstat to Johnson & Johnson's Janssen Biotech Inc. unit for $35 million upfront, the Menlo Park company said Thursday. The deal ultimately could be worth $900 million if certain development, regulatory and commercial milestones are hit over several years. Janssen will lead mid-stage studies of the drug in myelofibrosis, myelodysplastic syndrome and acute myelogenous leukemia. Development costs for the two studies in myelofibrosis,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 13, 2014 Category: Biotechnology Authors: Ron Leuty Source Type: news

Geron lands potential $900M blood cancer drug deal with J&J
Geron Corp. will hand over its experimental blood cancer drug imetelstat to Johnson & Johnson's Janssen Biotech Inc. unit for $35 million upfront, the Menlo Park company said Thursday. The deal ultimately could be worth $900 million if certain development, regulatory and commercial milestones are hit over several years. Janssen will lead mid-stage studies of the drug in myelofibrosis, myelodysplastic syndrome and acute myelogenous leukemia. Development costs for the two studies in myelofibrosis,… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - November 13, 2014 Category: Hospital Management Authors: Ron Leuty Source Type: news

Moffitt, M2Gen tapped to coordinate central laboratory, biorepository services for MDS
(H. Lee Moffitt Cancer Center & Research Institute) Moffitt Cancer Center and M2Gen have been awarded a contract from the National Institutes of Health's National Heart, Lung, and Blood Institute to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study (The National MDS Study). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 5, 2014 Category: Cancer & Oncology Source Type: news

M2Gen sets benchmark with $7.3M federal contract
Moffitt Cancer Center and M2Gen will play a central role in a new study of a group of blood disorders. The National Institutes of Health's National Heart, Lung, and Blood Institute awarded Moffitt and its for-profit subsidiary, M2Gen, a contract to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study. The $7.3 million project is the first federally funded contract for biorepository services at M2Gen, Moffitt's for-profit subsidiary,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 4, 2014 Category: American Health Authors: Margie Manning Source Type: news

A New Cancer Drug Worked In Over 25% Of Patients. What Does That Mean?
A new cancer drug, during a phase I trial, placed a patient with myelodysplastic syndrome in a complete remission that has lasted for more than three years. And it did so, in a non-invasive manner, setting forth a new way of treating cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 10, 2014 Category: Pharmaceuticals Authors: Jon Fortenbury Source Type: news

FDA News Roundup: Merck, UCB, Pfizer, Ipsen, And More
In the news this week, the FDA recently approved the first immunotherapy for melanoma, as well as drugs for epilepsy and myelodysplastic syndrome. The FDA also cleared several drugs for new indications, QIDP status, and orphan drug status. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - September 8, 2014 Category: Pharmaceuticals Source Type: news

Study identifies gene network behind untreatable leukemia, possible treatment target
Researchers have identified a genetic/molecular network that fuels a high-risk and aggressive form of acute myeloid leukemia and its precursor disease myelodysplastic syndrome -- providing a possible therapeutic strategy for an essentially untreatable form of the blood cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 4, 2014 Category: Science Source Type: news

Study identifies gene network behind untreatable leukemia and possible treatment target
(Cincinnati Children's Hospital Medical Center) Researchers have identified a genetic/molecular network that fuels a high-risk and aggressive form of acute myeloid leukemia and its precursor disease myelodysplastic syndrome -- providing a possible therapeutic strategy for an essentially untreatable form of the blood cancer. Scientists from the Cancer and Blood Diseases Institute at Cincinnati Children's Hospital Medical Center report their results in a study posted online Sept. 4 by Cell Reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 4, 2014 Category: Cancer & Oncology Source Type: news

MEI completes patient enrolment in Pracinostat Phase II trial for Myelodysplastic Syndrome
US-based oncology firm MEI Pharma has completed enrolment in a Phase II clinical trial of its lead investigational drug candidate, Pracinostat, in combination with azacitidine, to treat patients with previously untreated intermediate-2 or high-risk m… (Source: Drug Development Technology)
Source: Drug Development Technology - September 4, 2014 Category: Pharmaceuticals Source Type: news

Boston Strategics begins Phase I trial of anti-cancer agent to treat haematologic malignancies
Boston Strategics (BSC) has started a Phase I clinical trial of Fujifilm's anti-cancer agent FF-10501 in the US to treat patients with advanced haematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - September 2, 2014 Category: Pharmaceuticals Source Type: news

NHS England launches plan for a sustainable Cancer Drugs Fund
The amount pledged will give more patients access to innovative drugs not routinely available on the NHS. Two new drugs will now also be added to the Fund: enzalutamide for prostate cancer and lenalidomide for a group of patients with myelodysplastic syndrome, a rare blood condition. With an annual budget of £200m, now rising by 40 per cent to £280m, the Fund has delivered important benefits for more than 55,000 patients since it began in 2010. More .... (Source: NHS Networks)
Source: NHS Networks - August 29, 2014 Category: UK Health Authors: Maria Axford Source Type: news

NICE recommends Celgene’s Revlimid to treat myelodysplastic syndromes
The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Celgene's Revlimid (lenalidomide) to treat myelodysplastic syndromes (MDS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 21, 2014 Category: Pharmaceuticals Source Type: news

New NICE position on lenalidomide
NICE has issued final draft guidance recommending lenalidomide as an option for treating myelodysplastic syndromes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 20, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Haematology celgene Latest News lenalidomide myelodysplastic syndromes nice revlimid Source Type: news

NICE recommends lenalidomide for treating blood disorders
NICE has issued final draft guidance recommending lenalidomide, an immunomodulatory drug also known as Revlimid, as an option for treating myelodysplastic syndromes (MDS). (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - August 20, 2014 Category: Nursing Source Type: news

Exposure to inflammatory bowel disease drugs could increase leukemia risk
(American Gastroenterological Association) Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2014 Category: Cancer & Oncology Source Type: news

GSK initiates Phase III trial of eltrombopag-azacitidine combination in MDS patients
GlaxoSmithKline (GSK) has initiated a Phase III trial, SUPPORT (TRC112121), of eltrombopag in patients with myelodysplastic syndromes (MDS), a type of cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 26, 2014 Category: Pharmaceuticals Source Type: news

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™). (Source: GSK news)
Source: GSK news - June 25, 2014 Category: Pharmaceuticals Source Type: news